A ccumulating data suggest that Lp(a) is an important risk factor for both clinical and preclinical atherosclerotic vascular disease. [1] [2] [3] The Lp(a) particle is a normal LDL with apolipoprotein(a) glycoprotein attached to it by a disulfide bond. 1, 4 Interestingly, Lp(a) has also been implicated as a stimulus for smooth muscle cell proliferation, 5 and this might provide an additional role for Lp(a) in the pathogenesis of atherosclerosis.
Plasma Lp(a) levels are largely genetically determined. 6 Dietary and pharmacological attempts to reduce Lp(a) have been mainly unsuccessful. 7 Nicotinic acid, 8, 9 estrogen, 10,11 and alcohol [12] [13] [14] [15] are among the few factors that appear to lower Lp(a) levels. Lowered Lp(a) levels have also been observed during IGF-I administration. 16, 17 GH therapy has increased Lp(a) levels in normal subjects 18 and in patients with GH deficiency 19 and idiopathic osteoporosis. 17 However, GH therapy with near physiological doses in GH deficiency 20, 21 has no effect on Lp(a) levels.
Plasma Lp(a) levels are mainly determined by the apolipoprotein(a) production rate in the hepatocytes and the Lp(a) assembly. 22 Liver is also the main synthesis site of IGF-I 23 and IGFBP 1. 24 In fact, low levels of IGF-I have been detected during both estrogen replacement therapy 25, 26 and niacin therapy, 27 ie, in conditions with low Lp(a) levels. In addition, low levels of IGFBP-1, which is considered an acute regulator and inhibitor of IGF-I action, 28 were recently shown to be associated with multiple factors predisposing to atherogenesis. 29 Low Lp(a) levels have been observed in heavy alcohol consumers, 12, 13, 15 but the mechanisms behind the alcoholrelated reduction in Lp(a) are unknown. Since Lp(a) levels have been shown to rise rapidly after alcohol withdrawal, 13 we decided to study the changes in the GH/IGF-I/IGFBP-1 axis after alcohol withdrawal to evaluate whether GH, IGF-I, and IGFBP-1 might be related to the change seen in Lp(a) after alcohol withdrawal.
Methods Subjects
Twenty-eight consecutive male alcohol abusers admitted to the Alcoholism Treatment Unit in Oulu for withdrawal therapy were studied. Twenty-eight healthy nonalcoholic men volunteered as control subjects. One alcohol abuser with insulin-dependent diabetes mellitus and two control subjects with alcohol consumption of more than 40 g/d were excluded. The amount and quality of alcoholic beverages consumed during the previous 2 weeks were recorded using a questionnaire based on the method of Khavari and Farber. 30 All alcoholics had been drinking daily for at least 1 week before admission. Two of the control subjects were teetotalers and the others were social drinkers. The mean daily alcohol consumption was 232 g among the alcohol abusers and 13 g among the control subjects ( Table 1) .
All of the subjects had a good nutritional status and were clinically free from liver, kidney, or heart dysfunction. In one subject, albumin and Thrombotest Simplastin A (TT-SPA) levels were lower than normal (31 g/L and 59%, respectively), while the others presented with normal albumin levels [39 g/L (34 to 46 g/L) mean (range)] and TT-SPA values. The mean values (reference value) for alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), and mean corpuscular volume of erythrocytes (MCV) in the alcohol abusers were 57 U/L (Ͻ50 U/L), 162 U/L (Ͻ80 U/L), and 98 fL (Ͻ96 fL), respectively. MCV and the activities of ALT and GGT were analyzed in the laboratory of the Oulu University Hospital using standard methods. Written informed consent was obtained from all the participants, and the Ethical Committee of the University of Oulu approved the study.
Study Design
Venous blood samples were drawn after an overnight fast (between 7 and 8 AM) from the alcohol abusers on the first day after admission to the Alcoholism Treatment Unit and thereafter on three consecutive days during the abstinence period to investigate the changes in Lp(a), other lipids and lipoproteins, IGF-I, and IGFBP-1 related to alcohol withdrawal. An overnight (7 PM to 7 AM) urine collection for GH analyses was performed on 9 consecutive alcoholics on admission (before the first blood sampling day) and during the night before the fourth day of monitoring. Five control subjects were monitored for a 4-day period for Lp(a), IGF-I, IGFBP-1, and GH, while a single blood sample was obtained from the rest (nϭ21). Urine collection was performed among 11 control subjects. The plasma samples were stored at Ϫ70°C and the urine samples at Ϫ20°C.
Biochemical Assays
After isolating VLDL (dϽ1.006 g/mL) by ultracentrifugation, the HDL cholesterol concentration in the VLDL-free fraction was determined by an enzymatic method after precipitation of LDL with heparin-manganese chloride. 31 Plasma cholesterol and triglyceride concentrations were determined by enzymatic colorimetric methods (Boehringer, Mannheim GmbH) using a Kone Specific analyzer (Kone Specific, Selective Chemistry Analyzer, Kone Instruments).
Plasma Lp(a) concentrations were determined by an enzymelinked immunosorbent assay method (Biopool Ltd), which has been shown to correlate well with the other Lp(a) assay methods. 32 The CVs within and between Lp(a) assays were 5.0% and 6.6%, respectively. IGF-I was determined by a double antibody disequilibrium RIA (Incstar Stillwater) after an extraction procedure. The intra-assay CV was 5.9% and the interassay CV 11.8%. IGFBP-1 was measured by using an immunoenzymometric assay (IEMA TEST, Medix Biochemica), the intra-assay and interassay CVs being 4.1% and 8.6%, respectively. Urinary GH was determined by a sandwich RIA technique ( 125 I hGH U Coatria, bioMérieux) with a detection limit of 0.5 pg/mL. The intra-assay CVs at 1.4 and 13.6 pg/mL were 9.3% and 8.1%, respectively.
Statistical Analysis
Statistical analysis was carried out with the software package SPSS for Windows (Release 6.1, SPSS Inc.). The results are presented as meanϮSD unless otherwise stated. Logarithmic transformation was used to normalize the distribution of the data for Lp(a), GH, IGF-I, plasma, and VLDL triglycerides. A standard t test of means was then used to compare the homogeneity of the study groups. The strength of the linear association between two variables was measured using Pearson correlation coefficients. For analyses of the time-dependent changes in the variables, repeated-measures ANOVA module of SPSS was used. Thereafter, paired t tests were performed to evaluate the difference in the variables between days. GH and the variables that gave statistical significance (PϽ.05) after ANOVA were analyzed in a stepwise multiple linear regression model. In this procedure, independent variables that best predicted the value of the dependent variable were estimated by means of R 2 (explanatory value of the model).
Results
The alcohol abusers did not differ from the control subjects in age or BMI (Table 1 ). In contrast, the alcohol abusers had 75% higher plasma HDL cholesterol (PϽ.001) and 28% lower LDL cholesterol (PϽ.01) levels at the end of the drinking period compared with the control subjects. Lp(a), GH, IGF-I, and IGFBP-1 levels did not differ significantly between the groups (Table 1) , but Lp(a), GH, and IGF-I tended to be lower and IGFBP-1 higher in the alcoholics than in the control subjects.
Plasma lipids and lipoproteins, IGF-I, and IGFBP-1 in the alcoholics during the 4-day observation period after alcohol withdrawal are presented in Table 2 . Lp(a) levels increased by 64% after alcohol withdrawal (PϽ.001). Total and HDL cholesterol concentrations showed a reduction of 8% and 21%, respectively, while VLDL cholesterol and plasma TG did not change during the same period. An increase of 41% in IGF-I and a decrease of 59% in IGFBP-1 (PϽ.001 for both comparisons) levels were observed after the cessation of drinking. Urinary GH levels tended to decline during the monitoring period (from 2.56Ϯ3.14 to 1.10Ϯ1.00 pg/mL, PϭNS; meanϮSD). In the five control subjects who were monitored for 4 days, Lp(a), IGF-I, IGFBP-1, and GH levels did not change during a 4-day monitoring period (data not shown). 
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The change (from day 1 to day 4) in Lp(a) levels during the 4-day monitoring showed a negative association with the change in IGFBP-1 (rϭϪ.63, PϽ.001) (Fig 1) . In multiple regression analysis, the main predictors of the change in Lp(a) were IGFBP-1 alone or together with GH (R 2 ϭ.650, Pϭ.016 and R 2 ϭ.828, Pϭ.005, respectively). IGFBP-1 was also the main predictor of the change in plasma triglycerides (R 2 ϭ.530, Pϭ.026).
IGF-I
The change in IGF-I during the monitoring period did not show any correlation with the other variables. Multiple regression analysis revealed the best predictive parameters for the change in IGF-I to be plasma cholesterol and triglycerides (R 2 ϭ.850, Pϭ.003).
GH
The change in nocturnal (12 hours) urinary GH secretion correlated negatively with the change in plasma Lp(a) levels (rϭϪ.70, PϽ.05) (Fig 2) , but not with any other variables. The change in GH was best predicted by Lp(a) in the multiple regression analysis (R 2 ϭ.492, Pϭ.035).
Discussion
The three major findings in the present study were the following: (1) In agreement with a previous study, 13 Lp(a) levels increased rapidly after alcohol withdrawal. (2) Plasma levels of IGFBP-1 showed a remarkable decrease after the cessation of drinking, and the change correlated with that in Lp(a). The change in Lp(a) was mainly predicted by the changes in IGFBP-1 and GH. Conversely, Lp(a) was the main predictor for the changes in IGFBP-1 and GH. (3) The change in IGF-I after alcohol withdrawal mirrors the change seen in Lp(a) similarly to the change seen during niacin and estrogen therapies. [25] [26] [27] The increase in IGF-I related to alcohol withdrawal did not, however, correlate with the increase in Lp(a). This finding suggests that IGF-I may not be involved in the regulation of Lp(a) during alcohol withdrawal. The decreasing trend seen in the GH levels during the monitoring is suggested to reflect the negative feedback by increased IGF-I. Acute moderate alcohol intake has been shown to increase IGFBP-1 levels 33 and reduce GH levels. 34 Therefore, social alcohol consumption-shown to decrease Lp(a) levels 14 -may also have affected the GH/IGF-I/IGFBP-1 axis in the control group of the present study. This may partly explain why the control group, which mainly consisted of social drinkers, did not differ from the alcohol abusers in GH, IGF-I, IGFBP-1, and Lp(a) levels.
How could cessation of alcohol intake affect IGFBP-1 and Lp(a)? Alcohol alters the redox state of the liver by increasing the NADH/NAD ratio and thus promoting reduced intracellular state. 35 High NADH/NAD ratio is also characteristic for metabolic acidosis, a condition shown to increase plasma levels of IGFBP-1 and the IGFBP-1 content in the rat liver. 36 Theoretically, normalization of the redox state after alcohol withdrawal might have contributed to the observed reduction in IGFBP-1 levels. It is also possible that the removal of the hepatotoxic agent, ie, alcohol, allows the liver to resume its normal synthetic function and thus normalize IGFBP-1 and Lp(a) production. Since the rise in Lp(a) occurs rapidly, the mechanisms behind it may also be related to changes in the catabolism of Lp(a).
Nutritional factors are important in the regulation of IGF-I and IGFBP-1. 37, 38 Alcohol abusers may often present with hepatic damage and nutrient deprivation. 39, 40 However, a careful clinical examination of the subjects ruled out severe liver damage, and the normal BMI and serum albumin levels revealed that the subjects were in a good nutritional condition.
Previous data on the effects of alcohol on stress hormones, such as catecholamines and cortisol, are inconsistent. Increased 41 or unchanged 42 plasma cortisol levels have been observed after alcohol intake. IGF-I levels may be reduced 43 or unaffected 44 by corticosteroid excess. IGFBP-1 levels have been shown to decrease 45 or increase 46 during cortisol administration. In addition, dexamethasone treatment after renal transplantation has been shown to induce a dose-dependent reduction in Lp(a). 47 Therefore, the changes in Lp(a), IGF-I, and IGFBP-1 and the observed association between Lp(a) and IGFBP-1 during alcohol withdrawal are possibly not related to cortisol. Unfortunately, neither plasma nor urinary catecholamines and cortisol were measured in the present study.
Enhanced expression of IGF-I has been observed in human atherosclerotic plaques 48 and in rat allograft arteriosclerosis. 49 In addition, low levels of IGFBP-1 have recently been associated with low HDL cholesterol, increased insulin, proinsulin, and BMI-factors known to increase the risk for cardiovascular disease. 29 IGF-I was not shown to be associated with cardiovascular risk factors in that study. The present data provide new evidence that IGFBP-1 may also be associated with Lp(a), a risk factor for CHD. In the present study, alcohol withdrawal may have enhanced the bioavailability of IGF-I due to a concomitant increase in IGF-I and a decrease in IGFBP-1 levels. The role of GH may also be important in the modulation of Lp(a) levels, but this requires further studies, because the number of subjects analyzed for GH in the present study was limited.
In conclusion, alcohol withdrawal induces a rapid rise in plasma Lp(a) levels. The increase in Lp(a) is associated with the decrease in IGFBP-1. After cessation of drinking, IGF-I levels increase simultaneously with Lp(a), but they do not correlate with each other. Alcohol-induced changes in the liver, such as reduced redox state, could partly explain the observed changes in Lp(a) and IGFBP-1 levels seen after alcohol withdrawal. These changes, low IGFBP-1 together with high Lp(a), may be important factors predisposing to atherosclerosis. The possible interrelationship between Lp(a) and IGFBP-1 in a normal population awaits further studies.
